267 filings
8-K
BXRX
Baudax Bio, Inc.
28 Feb 24
Bankruptcy or Receivership
6:15am
25-NSE
The Nasdaq Stock Market LLC
15 Feb 24
Exchange delisting
8:53am
8-K
BXRX
Baudax Bio, Inc.
12 Dec 23
Other Events
9:52pm
424B3
BXRX
Baudax Bio, Inc.
22 Nov 23
Prospectus supplement
4:58pm
10-Q
2023 Q3
BXRX
Baudax Bio, Inc.
Quarterly report
20 Nov 23
5:28pm
NT 10-Q
0hkuggndh axp
15 Nov 23
Notice of late quarterly filing
5:25pm
8-K
pinuzbdduel5
15 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:07pm
8-K
dc1z8jb
25 Oct 23
Changes in Registrant's Certifying Accountant
7:57am
8-K
vyil025wm9a kcwtc
13 Oct 23
Submission of Matters to a Vote of Security Holders
7:00am
DEFA14A
6r4kwijqxm td5zj
10 Oct 23
Additional proxy soliciting materials
7:00am
8-K
nt3xfkkvyp
6 Oct 23
Departure of Directors or Certain Officers
8:00am
8-K
yll3p2exzp60g5
29 Sep 23
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
7:01am
EFFECT
xe0q ubli3y6z
26 Sep 23
Notice of effectiveness
12:15am
EFFECT
p6kyag89
26 Sep 23
Notice of effectiveness
12:15am
CORRESP
vp59ooouh gzqx
21 Sep 23
Correspondence with SEC
12:00am
CORRESP
fyuhg1bosxqhd ljsep8
21 Sep 23
Correspondence with SEC
12:00am
UPLOAD
9bnf8cr oz
13 Sep 23
Letter from SEC
12:00am